BDRX (Biodexa Pharmaceuticals) Other Financing: $-0.02 Mil (TTM As of Dec. 2025)


BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $3.00
GF Value $2.58
Valuation Modestly Overvalued
View Full Analysis

What is Biodexa Pharmaceuticals Other Financing?

Biodexa Pharmaceuticals BDRX +0.67% 45 Other Financing is $-0.02 Mil as of Dec. 2025. GuruFocus rates BDRX with a GF Score™ of 45/100 and a GF Value™ of $2.58 (Modestly Overvalued).

Biodexa Pharmaceuticals's Other Financing for the six months ended in Dec. 2025 was $-0.01 Mil.

Biodexa Pharmaceuticals's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.02 Mil.

Biodexa Pharmaceuticals Other Financing Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Other Financing Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.20 -0.02 0.00 -0.02

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 0.00 -0.01 -0.01
BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.02 Mil mean?
Biodexa Pharmaceuticals (BDRX) has a Other Financing of $-0.02 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Other Financing too high?
Biodexa Pharmaceuticals' current Other Financing is $-0.02 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Other Financing compare to ADTX and AAGH?
Biodexa Pharmaceuticals' Other Financing of $-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Other Financing is $-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biodexa Pharmaceuticals (BDRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.58, compared to a current price of $3.00 — trading 16.3% above its estimated fair value. The current Other Financing is $-0.02 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current Other Financing is $-0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $3.00 is trading 16.3% above its estimated GF Value™ of $2.58. GuruFocus considers Biodexa Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for BDRX:

  • Other Financing: $-0.02 Mil
  • GF Value™: $2.58 vs. price of $3.00 (16.3% above fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.00
Price
$2.58
GF Value